As cancer immunotherapies induce gut microbiome perturbations and immune-mediated adverse events in susceptible patients, we hypothesized that NOD mice can be used as a predictive tool to investigate the effects of anti–PD-1 treatment on the onset and severity of T1D, and how microbiota influences immunopathology. This evidence concerns the gene PDCD1 and cancer.